| Identification | Back Directory | [Name]
Benzaldehyde, 5-fluoro-2-[[1-[(3-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy]- | [CAS]
2276711-87-4 | [Synonyms]
Xanthine oxidase-IN-5
Benzaldehyde, 5-fluoro-2-[[1-[(3-methoxyphenyl)methyl]-1H-1,2,3-triazol-4-yl]methoxy]- | [Molecular Formula]
C18H16FN3O3 | [MOL File]
2276711-87-4.mol | [Molecular Weight]
341.34 |
| Hazard Information | Back Directory | [Uses]
Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model[1]. | [in vivo]
Xanthine oxidase-IN-5 (compound 9m) shows potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate[1]. | Animal Model: | Potassium oxonate-induced hyperuricemic rat model[1] | | Dosage: | 20 mg/kg | | Administration: | PO; single (measured serum uric acid after 0.5 - 8 hours) | | Result: | Showed potent hypouricemic effects at an oral dose of 20 mg/kg in a rat hyperuricemia model induced by potassium oxonate. |
| [References]
[1] Zhang TJ, Zhang Y, Zhang ZH, et al. Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2022;60:128582. DOI:10.1016/j.bmcl.2022.128582 |
|
|